UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 20 Park Plaza, Suite 424 Boston, Massachusetts (Commission File Number) 10216 (Zip Code) Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 240.14s-12) Pre-commencement communications pursuant to Rule 14s-12 under the Exchange Act (17 CFR 240.14s-12) Pre-commencement communications pursuant to Rule 14s-(2) under the Exchange Act (17 CFR 240.14s-12) Pre-commencement communications pursuant to Rule 13s-4(c) under the Exchange Act (17 CFR 240.14s-12) Pre-commencement communications pursuant to Rule 13s-4(c) under the Exchange Act (17 CFR 240.13s-4(c)) Title of each class CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1931 (§230.405 of this chapter) Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any nor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 January 4, 2024 Date of Report (Date of earliest event reported) CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction (Commission (I.R.S. Employer Identification No.) 20 Park Plaza, Suite 424 Boston, Massachusetts (Address of principal executive offices) Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 144-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14a-4(c)) Pre-commencement communications pursuant to Rule 13a-4(c) under the Exchange Act (17 CFR 240.14a-4(c)) Trading Symbol(s) Name of each exchange on which registrant Common Stock, So.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any any and the securities are complying with any and the securities		FORM 8-K	
CervoMed Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction (Commission (I.R.S. Employer Identification No.) 20 Park Plaza, Suite 424 Boston, Massachusetts 02216 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, \$0.001 par value CRVO NASDAO (Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any and		Pursuant to Section 13 or 15(d)	
Commission Com	Date		d)
Delaware (State or other jurisdiction of incorporation) Registrant's telephone number, including area code: (617) 744-4400 Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Symbol(s) Name of each exchange on which registered Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (\$230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (\$240.12b-2 of this chapter). Emerging growth company	Œ		
(State or other jurisdiction of incorporation) (Commission File Number) (LR.S. Employer Identification No.) 20 Park Plaza, Suite 424 Boston, Massachusetts (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.14a-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading File of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not the securities and the securities and transition period for complying with any not the securities and the s	(-		
Boston, Massachusetts (Address of principal executive offices) Registrant's telephone number, including area code: (617) 744-4400 Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Name of each exchange Title of each class Symbol(s) NASDAQ Capital Market Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any no	(State or other jurisdiction	(Commission	(I.R.S. Employer
Not applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Symbol(s) Name of each exchange on which registered Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company	Boston, Massachusetts		
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading	Registrant	t's telephone number, including area code: (617) 7	44-4400
Gollowing provisions: □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) □ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ■ Trading Name of each exchange on which registered Symbol(s)	(Forme		port)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) □ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Name of each exchange Title of each class Symbol(s) on which registered Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company □ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not appear to the securities and the registrant has elected not to use the extended transition period for complying with any not appear to the securities and the registrant has elected not to use the extended transition period for complying with any not appear to the securities and the securities are the securiti	* * *	ing is intended to simultaneously satisfy the filing ob	ligation of the registrant under any of the
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Symbol(s) Trading Symbol(s) Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company □ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any market.	☐ Written communications pursuant to Rule 425 un	nder the Securities Act (17 CFR 230.425)	
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Trading Symbol(s) Trading Name of each exchange on which registered Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company □ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any not accompanied to the securities accomplying with any not accompanied to the securities accomplying with any not accompanied to the securities accompanied to th	☐ Soliciting material pursuant to Rule 14a-12 under	er the Exchange Act (17 CFR 240.14a-12)	
Trading Symbol(s) Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any many many many many many many many	$\ \square$ Pre-commencement communications pursuant to	Rule 14d-2(b) under the Exchange Act (17 CFR 24d	0.14d-2(b))
Title of each class Common Stock, \$0.001 par value CRVO NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company □ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any negative statements.	☐ Pre-commencement communications pursuant to	o Rule 13e-4(c) under the Exchange Act (17 CFR 240	0.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new tensor of the securities act of 1934 (§240.12b-2 of this chapter).	Title of each class	_	on which registered
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new company.	Common Stock, \$0.001 par value	CRVO	NASDAQ Capital Market
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any n			he Securities Act of 1933 (§230.405 of this
	Emerging growth company \square		
			ed transition period for complying with any new

Item 7.01. Regulation FD Disclosure

Corporate Presentation

Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.

The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.

The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 4, 2024 CervoMed Inc.

By: /s/ William Elder

Name: William Elder
Title: General Counsel